Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

NCT04903197 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

18

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision and not due to any safety or tolerability concerns.

Conditions

Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

Interventions

DRUG: VAY736
DRUG: lenalidomide

Sponsor

Novartis Pharmaceuticals